Freedom of Information

How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
• Amivantamab
• Atezolizumab Monotherapy
• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
• Dabrafenib + Trametinib
• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
• Durvalumab
• Gemcitabine
• Nitedanib + Docetaxel
• Nivolumab
• Osimertinib
• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
• Paclitaxel
• Pembrolizumab Monotherapy
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
• Pemetrexed + Platinum (Carboplatin/Cisplatin)
• RET Inhibitors (Pralsetinib, Selpercatinib)
• Sotorasib
• Tepotinib
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
• Other active systemic anti-cancer therapy
• Palliative care only

How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
• Atezolizumab monotherapy
• Durvalumab
• Gemcitabine
• Nivolumab
• Osimertinib
• Pembrolizumab (Keytruda) Mono
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
• Paclitaxel
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
• Other active systemic anti-cancer therapy (SACT)
• Palliative care only